Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Healthtrust
Fuji
Colorcon
UBS
Merck
McKesson
AstraZeneca
Dow

Generated: May 24, 2018

DrugPatentWatch Database Preview

Sarepta Theraps Inc Company Profile

« Back to Dashboard

What is the competitive landscape for SAREPTA THERAPS INC, and when can generic versions of SAREPTA THERAPS INC drugs launch?

SAREPTA THERAPS INC has one approved drug.

There are five US patents protecting SAREPTA THERAPS INC drugs.

There are one hundred and sixty patent family members on SAREPTA THERAPS INC drugs in twenty-three countries.

Summary for Sarepta Theraps Inc
International Patents:160
US Patents:5
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Sarepta Theraps Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sarepta Theraps Inc EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488-001 Sep 19, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up
Sarepta Theraps Inc EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488-001 Sep 19, 2016 RX Yes Yes 9,018,368 ➤ Sign Up Y Y ➤ Sign Up
Sarepta Theraps Inc EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488-002 Sep 19, 2016 RX Yes Yes 9,506,058 ➤ Sign Up ➤ Sign Up
Sarepta Theraps Inc EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488-002 Sep 19, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Sarepta Theraps Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,895,722 Splice-region antisense composition and method ➤ Sign Up
8,501,704 Immunosuppression compound and treatment method ➤ Sign Up
8,168,604 Antisense antiviral compounds and methods for treating a filovirus infection ➤ Sign Up
8,436,163 Splice-region antisense composition and method ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Healthtrust
Merck
Chinese Patent Office
Medtronic
Harvard Business School
Cipla
Cantor Fitzgerald
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.